Abstract

This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies.

Details

Title
Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
Author
Ingen-Housz-Oro, Saskia 1   VIAFID ORCID Logo  ; Thibault, Constance 2 ; Sohier, Pierre 3 ; Dupin, Nicolas 4 

1  Dermatology Department, Henri Mondor Hospital, AP-HP, Univ Paris-est Créteil EpidermE , Créteil , France 
2  Oncology Department, Georges Pompidou Hospital , AP-HP, Paris , France 
3  Pathology Department, Cochin Hospital, AP-HP, AP-HP.Centre-Université Paris Cité, Paris , France 
4  Dermatology Department, AP-HP, Cochin Hospital , Paris , France 
Pages
e825-e826
Publication year
2022
Publication date
Oct 2022
Publisher
Oxford University Press
ISSN
10837159
e-ISSN
1549490X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/oncolo/oyac170
ProQuest document ID
3191346647
Copyright
© The Author(s) 2022. Published by Oxford University Press. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.